Literature DB >> 1370173

Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro.

R A Swerlick1, K H Lee, T M Wick, T J Lawley.   

Abstract

CD36 is an 88-kDa glycoprotein that has been identified on platelets, monocytes, and some endothelial cells. Experimental evidence suggests that CD36 mediates the binding of Plasmodium falciparum-infected RBC to a variety of cells, and therefore may play a role in the vascular complications associated with malaria. Additionally, CD36 may also bind the extracellular matrix proteins thrombospondin and collagen. Human umbilical vein endothelial cells have been used in in vitro models examining the binding of P. falciparum RBC to endothelial cells, but they do not consistently express cell surface CD36. Inasmuch as human dermal microvascular endothelial cells (HDMEC) differ in a variety of ways from large vessel endothelial cells, we have examined HDMEC for cell surface expression of CD36 in vivo and in vitro. Direct immunofluorescence of skin showed bright staining of HDMEC with antibody recognizing CD36 and flow cytometric analysis of cultured HDMEC revealed cell surface expression. In contrast, large vessel endothelial cells were not stained with antibody recognizing CD36 in vivo and cultured cells derived from umbilical vein failed to express cell surface CD36 in vitro. Western immunoblots of lysates of HDMEC but not human umbilical vein endothelial cells demonstrated an 88-kDa protein that comigrated with CD36 from platelets. Functional studies demonstrated that adherence of PRBC to HDMEC was inhibited up to 66% by mAb recognizing CD36. Furthermore, the expression of CD36 on HDMEC was increased in a dose- and time-dependent manner by IFN-gamma, and was decreased by protein kinase C agonists. These data demonstrate that HDMEC express functionally active CD36 and this expression can be positively and negatively regulated by soluble factors. This study demonstrates that HDMEC are useful in the study of CD36-mediated binding of PRBC to endothelial cells in vitro and provides further evidence of distinct phenotypic differences between HDMEC and large vessel endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370173

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  A modified Boyden chamber assay for tumor cell transendothelial migration in vitro.

Authors:  Y H Li; C Zhu
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

2.  Origins of circulating endothelial cells and endothelial outgrowth from blood.

Authors:  Y Lin; D J Weisdorf; A Solovey; R P Hebbel
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1.

Authors:  L Chandrasekaran; C Z He; H Al-Barazi; H C Krutzsch; M L Iruela-Arispe; D D Roberts
Journal:  Mol Biol Cell       Date:  2000-09       Impact factor: 4.138

4.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.

Authors:  Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-15       Impact factor: 11.205

5.  Selective induction of cell adhesion molecules by proinflammatory mediators in human cardiac microvascular endothelial cells in culture.

Authors:  Jun Yan; Adrian D Nunn; Regi Thomas
Journal:  Int J Clin Exp Med       Date:  2010-10-23

6.  Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.

Authors:  Keiko Takahashi; Raymond L Mernaugh; David B Friedman; Rebecca Weller; Nobuo Tsuboi; Hironobu Yamashita; Vito Quaranta; Takamune Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

7.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  Myeloid receptor CD36 is required for early phagocytosis of myocardial infarcts and induction of Nr4a1-dependent mechanisms of cardiac repair.

Authors:  Shirley Dehn; Edward B Thorp
Journal:  FASEB J       Date:  2017-08-31       Impact factor: 5.191

Review 9.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

10.  Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium.

Authors:  Marie-Marcelle Trinh-Trang-Tan; Camilo Vilela-Lamego; Julien Picot; Marie-Paule Wautier; Jean-Pierre Cartron
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.